Genitourinary Cancer | Norton Healthcare

Indication: Genitourinary Cancer

An Expanded/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Sub-indication: Genitourinary Cancer

Drug Study

Principal Investigator: Chandler Park, M.D.
Norton Cancer Institute

Sponsor: Suzhou Kintor Pharmaceuticals, Inc.

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.